Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192153 · ClinicalTrials.gov registry record · Phase 2
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00192153 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 240 participants.
The verdict
NCT00192153, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to develop assays for application in investigating potential immunological correlates of protection and/or establishing assays to measure vaccine take.
Interventions
- BIOLOGICAL CAIV-T or TIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2001-07 |
| Est. Completion | 2001-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192153
The ClinicalTrials.gov registry entry for NCT00192153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAIV-T or TIV is the first listed.
NCT00192153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192153 about?
NCT00192153 is a clinical study titled "Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older". The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to develop assays for application in investigating potential immunological c...
What is the current status of trial NCT00192153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2001-07. Estimated completion is 2001-10.
What interventions are being tested in trial NCT00192153?
The interventions under investigation include: CAIV-T or TIV (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192153?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.